Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

RLY-2608

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Relay Therap

Drug class:

pan-mutant PIK3CA-selective inhibitor

Related drugs:

‹

›

PIK3CA E545K	Hormone Receptor Positive Breast Cancer	PIK3CA E545K	Hormone Receptor Positive Breast Cancer	abemaciclib + RLY-2608 Sensitive: D – Preclinical abemaciclib + RLY-2608 Sensitive : D	abemaciclib + RLY-2608 Sensitive: D – Preclinical abemaciclib + RLY-2608 Sensitive : D
PIK3CA E545K	Hormone Receptor Positive Breast Cancer	PIK3CA E545K	Hormone Receptor Positive Breast Cancer	palbociclib + RLY-2608 Sensitive: D – Preclinical palbociclib + RLY-2608 Sensitive : D	palbociclib + RLY-2608 Sensitive: D – Preclinical palbociclib + RLY-2608 Sensitive : D
PIK3CA H1047R	Hormone Receptor Positive Breast Cancer	PIK3CA H1047R	Hormone Receptor Positive Breast Cancer	abemaciclib + RLY-2608 Sensitive: D – Preclinical abemaciclib + RLY-2608 Sensitive : D	abemaciclib + RLY-2608 Sensitive: D – Preclinical abemaciclib + RLY-2608 Sensitive : D
PIK3CA H1047R	Hormone Receptor Positive Breast Cancer	PIK3CA H1047R	Hormone Receptor Positive Breast Cancer	palbociclib + RLY-2608 Sensitive: D – Preclinical palbociclib + RLY-2608 Sensitive : D	palbociclib + RLY-2608 Sensitive: D – Preclinical palbociclib + RLY-2608 Sensitive : D
PIK3CA H1047R	Hormone Receptor Positive Breast Cancer	PIK3CA H1047R	Hormone Receptor Positive Breast Cancer	RLY-2608 Resistant: D – Preclinical RLY-2608 Resistant : D	RLY-2608 Resistant: D – Preclinical RLY-2608 Resistant : D
PIK3CA E545K	Hormone Receptor Positive Breast Cancer	PIK3CA E545K	Hormone Receptor Positive Breast Cancer	RLY-2608 Resistant: D – Preclinical RLY-2608 Resistant : D	RLY-2608 Resistant: D – Preclinical RLY-2608 Resistant : D